Pricing and Reimbursement Issues for Pharmaceutical Products in Europe

Published by: Frost & Sullivan

Published: Nov. 23, 2005 - 155 Pages

Table of Contents

1. Executive Summary

        1. Executive Summary

                1. Summary of the Pricing and Reimbursement Issues for Pharmaceutical Products in Europe

2. European Union

        1. Overview

                1. Scope

                2. Key Abbreviations

                3. Introduction

                4. The Pharmaceutical Expenditure in EU

                5. Pricing and Reimbursement

                6. Issues with Pharmaceutical Pricing and Reimbursement in EU

3. Austria

        1. Austria

                1. Pharmaceutical in Austria

                2. Austrian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

4. Belgium

        1. Belgium

                1. Pharmaceutical in Belgium

                2. Belgian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

5. Czech Republic

        1. Czech Republic

                1. Pharmaceutical in Czech Republic

                2. Czech Republic Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

6. Denmark

        1. Denmark

                1. Pharmaceutical in Denmark

                2. Denmark Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

7. Estonia

        1. Estonia

                1. Pharmaceutical in Estonia

                2. Estonia Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

8. Finland

        1. Finland

                1. Pharmaceutical in Finland

                2. Finnish Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

9. France

        1. France

                1. Pharmaceutical in France

                2. French Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

10. Germany

        1. Germany

                1. Pharmaceutical in Germany

                2. German Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

11. Greece

        1. Greece

                1. Pharmaceutical in Greece

                2. Greece Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

12. Hungary

        1. Hungary

                1. Pharmaceutical in Hungary

                2. Hungarian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

13. Ireland

        1. Ireland

                1. Pharmaceutical in Ireland

                2. Irish Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

14. Italy

        1. Italy

                1. Pharmaceutical in Italy

                2. Italian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

15. Latvia

        1. Latvia

                1. Pharmaceutical in Latvia

                2. Latvia Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

16. Lithuania

        1. Lithuania

                1. Pharmaceutical in Lithuania

                2. Lithuanian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

17. Poland

        1. Poland

                1. Pharmaceutical in Poland

                2. Polish Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

18. Portugal

        1. Portugal

                1. Pharmaceutical in Portugal

                2. Portugal Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

19. Slovakia

        1. Slovakia

                1. Pharmaceutical in Slovakia

                2. Slovakian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

20. Slovenia

        1. Slovenia

                1. Pharmaceutical in Slovenia

                2. Slovenian Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

21. Spain

        1. Spain

                1. Pharmaceutical in Spain

                2. Spanish Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

22. Sweden

        1. Sweden

                1. Pharmaceutical in Sweden

                2. Swedish Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

23. Switzerland

        1. Switzerland

                1. Pharmaceutical in Switzerland

                2. Switzerland Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

24. The Netherlands

        1. The Netherlands

                1. Pharmaceutical in the Netherlands

                2. The Netherlands Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

25. The United Kingdom

        1. The United Kingdom

                1. Pharmaceutical in the United Kingdom

                2. The United Kingdom Pharmaceutical and Healthcare Industry SWOT Analysis

                3. Pharmaceutical Pricing and Reimbursement

                4. Industry Issues

26. Strategic Analysis and Recommendations

        1. Pricing and Reimbursement Strategies

                1. Pricing and Reimbursement

                2. Early Drug Development Phase– A “Foundation Level” Pharmaceutical Pricing and Reimbursement Strategies

                3. Mid and Late Drug Development Phase – Pharmaceutical Pricing and Reimbursement Strategies

                4. The Decision Phase and Market Entry

                5. The Post Launch Phase

List of Figures

Chapter 2

• Pharmaceutical Pricing and Reimbursement: Pharmaceutical Price Structure (Europe), 2003 and 2005


• Pharmaceutical Pricing and Reimbursement: VAT Rates (Europe), 2003


• Pharmaceutical Pricing and Reimbursement: Pharmaceutical Expenditure in Per cent of Total Healthcare Expenditures (Europe), 1992 and 2000

Chapter 10

• Pharmaceutical Pricing and Reimbursement: Comparison of Pharmaceutical Prices (Europe), 2004

Abstract

Proportion of Pharmaceutical Spending in the Total Healthcare Expenditure Sees an Increase

Despite most EU member states having publicly funded healthcare systems, private spending remains high in respect to the pharmaceutical sector. Pharmaceutical expenditure is largely private in countries such as Denmark and Belgium. The pharmaceutical expenditure has also been mostly private in Italy until recently. Moreover, due to cost-containment attempts, the proportion of public share in pharmaceutical expenditure is already decreasing in some of the other EU states. Nevertheless, the levels of the decline in the public proportion remains low in countries such as the United Kingdom, the Netherlands, Portugal and Sweden, that are, on the contrary, witnessing an increase in the amount of public spending on pharmaceutical expenditure. Overall, the proportion of pharmaceutical spending in the total healthcare expenditure continues to increase throughout the region.

This Frost & Sullivan research service is a strategic analysis of pricing and reimbursement issues for pharmaceutical products in Europe. It analyses the pharmaceutical pricing and reimbursement system for 23 European countries, providing a comprehensive understanding of the system in each country. Further, the strengths, weaknesses, opportunities and threats (SWOT) analysis provided for each country is expected to enable multi-national pharmaceutical and biotechnology companies to identify local strengths and weaknesses and better utilise the opportunities available in each country.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.